Colchicine Treatment May Lower Risk for Cardiovascular Events in Chronic Coronary Disease
Daily colchicine treatment may reduce the risk for cardiovascular events in patients with chronic coronary disease.
Daily colchicine treatment may reduce the risk for cardiovascular events in patients with chronic coronary disease.
Decompensation severity may be associated with increased risk for adverse clinical outcomes post-hospital discharge in patients with first-episode acute heart failure.
Worsening renal function may be associated with left ventricular ejection fraction in patients with acute heart failure.
Arrhythmia-free survival after catheter ablation for atrial fibrillation was comparable in patients with heart failure with preserved and reduced ejection fraction.
Therapies which improve endothelial dysfunction should be considered for the treatment of patients with COVID-19-and acute coronary syndrome.
Angiographic co-registration-guided percutaneous coronary intervention outperformed other methods for reducing major edge dissection and longitudinal geographic mismatch.
Gout was not found to be associated with increased risk for cardiovascular complications in patients with peripheral artery disease.
Multimodal lipid lowering therapy may be regularly adjusted in patients with bi-allelic familial hypercholesterolemia based on ultrasounds of all accessible arteries.
Early menarche was found to be associated with poorer cardiovascular health.
Suggestions were formulated to reduce bias and error related to the use of machine learning approaches in cardiology research.